Cidara Therapeutics, Inc. - Common Stock (CDTX)

Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.

This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.

This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.

This clinical-stage biotech develops therapies for CML, NASH, and obesity.

Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors who held the stock prior to today’s session are now locked in to receive a quarterly payout of $0.85 per

This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.

CSG Systems International delivers SaaS-based billing and customer engagement solutions to telecom and enterprise clients worldwide.

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the industry has closed the year with a powerful rally, fueled by a dovish shift from the Federal Reserve and

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts by surprise. After years of trading in the shadow of high interest rates and regulatory uncertainty, the industry

After a long hiatus, why are the bulls so willing to buy in now?

The rebound is well underway.

There are plenty of potential winners outside the world of AI.

The struggling pharmaceutical giant is showing signs of life.

Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter

Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way

The pharmaceutical giant's post-Keytruda plans continue to take shape.

Shares in the biotech company have surged on news of a big pharma takeover.

Bain Capital sold its entire stake in Nuvalent stock during the third quarter.

Bain Capital completely exited its position in Disc Medicine stock during the third quarter

Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.